VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

VivoSim Labs, Inc. (NASDAQ:VIVS) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 570,467 shares, a growth of 1,070.7% from the July 15th total of 48,730 shares. Based on an average trading volume of 8,475,803 shares, the days-to-cover ratio is presently 0.1 days. Approximately 16.7% of the company’s shares are short sold.

VivoSim Labs Stock Down 3.2%

Shares of VivoSim Labs stock traded down $0.01 on Tuesday, hitting $0.35. The company had a trading volume of 3,220,143 shares, compared to its average volume of 16,634,510. The stock has a 50-day moving average of $0.81 and a 200-day moving average of $1.39. VivoSim Labs has a twelve month low of $0.31 and a twelve month high of $5.30.

VivoSim Labs (NASDAQ:VIVS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($2.21) EPS for the quarter. The company had revenue of $0.04 million for the quarter. VivoSim Labs had a negative return on equity of 277.62% and a negative net margin of 10,567.17%.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.